To Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients With Conjunctivochalasis

Conjunctivochalasis Clinical Trial

Official title:
A Randomized, Double-Blind, Placebo-Controlled, Pilot Study to Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients With Moderate to Severe Conjunctivochalasis

Status Completed

Clinical Trial Summary

A Randomized, Double-Blind, Placebo-Controlled, Pilot Study to Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients with Moderate to Severe Conjunctivochalasis

Clinical Trial Description

Phase 2a, randomized, placebo-controlled, pilot study in up to 21 adult patients with moderate to severe CCh. Eligible patients will be randomly assigned in a 2:1 (active:placebo) ratio to one of two treatment groups, LO2A or placebo.

This study with 4 visits, will consist of a screening period of up to 2 weeks and a 3-month treatment period (topical, OU, QID application of eye drops). ;

Study Design

Related Conditions & MeSH terms

Conjunctivochalasis

Clinical Trial Details

NCT number	NCT02810119
Study type	Interventional
Source	Ocuwize LTD
Contact
Status	Completed
Phase	Phase 2
Start date	November 2016
Completion date	October 2017

View Details

See also
	Status	Clinical Trial	Phase
	Active, not recruiting	`NCT02160327` - The Role of Cytokines and Mast Cell in the Pathogenesis of SLK, Conjunctivochalasis, and Dry Eye	N/A
	Completed	`NCT02804191` - Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients With Moderate to Severe Conjunctivochalasis	Phase 2